Press Release

Abbott’s ® (Adalimumab) Meets Primary Endpoints in Phase III Study

May 10, 2011

Abbott Park, Illinois (NYSE: ABT) — Abbott’s HUMIRA® (adalimumab) met its primary endpoint of clinical in a Phase III study of with moderate to severe ulcerative colitis. Results were presented at the (DDW) scientific conference in Chicago.

Ulcerative colitis (UC) is a that causes and ulceration in the lining of the colon or large intestine. It is estimated that approximately 700,000 people in the United States have UC. Symptoms include , rectal bleeding, increased and .

Reads Full Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study Press Release

About Robert Hill

I founded IDEAS Intestinal Disease Education and Awareness Society, from my home base in Vancouver, British Columbia. Intestinal Disease Education and Awareness Society IDEAS is established to raise public awareness of intestinal diseases in order to help remove the stigmas associated with these illnesses. The programs of IDEAS help children, youth and young adults learn to live full lives, find acceptance and gain confidence.

Leave a Reply